文献速递心血管胸部技术与安全USMRCTPET

多模态影像评估癌症患者的心血管毒性

Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient.
PubMed 文献 · JACC Cardiovasc Imaging · 2018-01-01

综述阐述多模态先进影像可用于癌症患者心血管毒性危险分层、疗中及疗后损伤识别与恢复预测;超声心动图(含应变成像)是评估心脏毒性主要手段,心脏磁共振(CMR)为补充,T1/T2 mapping 与 PET 有助理解心肌结构、病理与代谢改变,负荷超声、负荷 CMR、CT 和 PET 可用于评估治疗相关血管痉挛或动脉粥样硬化加速所致缺血。

要点

  • 超声心动图(尤其应变成像)是评估癌症治疗心脏毒性的主要手段。
  • CMR 用于超声或平衡法核素血管造影图像质量差、需更准确左室射血分数时。
  • 负荷超声、负荷 CMR、CT 和 PET 可用于评估治疗相关缺血。

核心结论

  • 先进多模态影像可用于癌症患者心血管毒性危险分层、疗中及疗后心血管损伤识别并预测恢复。

研究设计与样本

  • 综述,检索范围与纳入文献原文未报告。

关键影像表现/征象

  • 超声心动图是评估心脏毒性的主要手段。
  • 基于超声心动图的应变成像有助基线危险分层及疗中检出亚临床左室功能不全。
  • CMR 在超声或平衡法核素血管造影图像质量差、或需更准确左室射血分数以决定是否停用化疗时起补充作用。
  • T1 和 T2 mapping 及 PET 成像有助更好理解与心室功能不全或血清生物标志物释放相关的心肌结构、病理和代谢改变。
  • CMR 可能有助于评估癌症治疗的血管并发症。

临床应用与阅片要点

  • 超声心动图(含应变成像)用于癌症患者基线危险分层及疗中监测亚临床左室功能不全。
  • 超声或平衡法核素血管造影图像质量差、或需更准确左室射血分数指导化疗停药决策时,可用 CMR 补充。
  • 接受可能引起血管痉挛或动脉粥样硬化加速治疗的患者,评估缺血可选负荷超声、负荷 CMR、CT 和 PET。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Cancer therapy can be associated with both cardiac and vascular toxicity. Advanced multi-modality imaging can be used to stratify patient risk, identify cardiovascular injury during and after therapy, and forecast recovery. Echocardiography continues to be the mainstay in the evaluation of cardiac toxicity. Particularly, echocardiography-based strain imaging is useful for risk stratification of patients at baseline, and detection of subclinical left ventricle (LV) dysfunction during therapy. Cardiac magnetic resonance (CMR) serves a complementary role in the patient with poor echocardiographic or equilibrium radionuclide angiographic image quality or in situations where a more accurate and precise LV ejection fraction measurement is needed to inform decisions regarding discontinuation of chemotherapy. New CMR techniques like T1 and T2 mapping and positron emission tomography (PET) imaging will help us better understand the structural, pathological, and metabolic myocardial changes associated with ventricular dysfunction or release of serum biomarkers. CMR may also be helpful in the evaluation of vascular complications of cancer therapy. Stress echocardiography, stress CMR, computed tomography, and PET are excellent imaging options in the evaluation of ischemia in patients receiving therapies that could potentially cause vasospasm or accelerated atherosclerosis.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, et al. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. JACC Cardiovasc Imaging. 2018. PMID: 30092972. doi:10.1016/j.jcmg.2018.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。